10 January 2020 : Clinical Research
Body Mass Index and Major Adverse Cardiovascular Events: A Secondary Analysis Based on a Retrospective Cohort Study
Xiaobo Liu1ABCDEFG, Peng Liu2ABCDEFG*DOI: 10.12659/MSM.919700
Med Sci Monit 2020; 26:e919700
Abstract
BACKGROUND: The association between body mass index (BMI) and major adverse cardiovascular events (MACE) has not been clarified and is controversial. Therefore, the purpose of present study is to explore the association between BMI and MACE.
MATERIAL AND METHODS: This was a secondary analysis of a retrospective cohort study in which 204 participants who were diagnosed with stable coronary artery disease (CAD) and received elective percutaneous coronary intervention (PCI) were recruited. According to the BMI, patients were divided into 3 categories – underweight (BMI <18.5 kg/m²), normal BMI (18.5 ≤BMI <25 kg/m²), and overweight (BMI ≥25 kg/m²)], and the patients were followed up. The primary endpoint was MACE.
RESULTS: After a median follow-up of 783 days, MACE events had occurred in 18 participants. After controlling for potential confounding factors, no difference was observed in MACE between the underweight group and the normal BMI group (OR=1.73, 95% CI 0.42 to 7.17); but there were significantly fewer MACE in the overweight group than in the normal BMI group (OR=0.17; 95% CI: 0.03 to 0.84). Pearson correlation analysis showed that BMI was positively correlated with hemoglobin (r=0.2102) and albumin (r=0.2780), but negatively correlated with high-density lipoprotein cholesterol (r=–0.2052). The receiver operating characteristic curve (ROC) showed that the best threshold for BMI to predict MACE was 24.23, the area under the curve was 0.729, sensitivity was 0.893, and the specificity was 0.460.
CONCLUSIONS: Our study shows that overweight patient with stable CAD have lower risk of MACE after PCI, and the optimal threshold for predicting MACE is 24.23.
Keywords: Body Mass Index, Cardiovascular Abnormalities, percutaneous coronary intervention, Cardiovascular Diseases, Multivariate Analysis, ROC Curve, Regression Analysis
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952